Nearly one year ago, Gilead announced its ‘access initiative’ promising lower prices for liposomal amphotericin B in 116 developing countries, but to date, the drug largely remains inaccessible.
‘Gilead’s key drug used in HIV-related infection out of reach in developing countries’
More from Industry NewsMore posts in Industry News »
- Frontline, medical workers need to take booster shots, say experts
- India tells Quad will allow export of 8 mln Indo-Pacific vaccine doses
- We need to be vigilant towards counterfeit products: Nakul Pasricha,President, ASPA
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference